Scientists have engineered a monoclonal antibody that can protect mice from a lethal dose of influenza A, a new study shows.

Sales started to slow in the spring, as market uncertainty began to weigh on investor confidence, says CEO James O’Sullivan ...

US biotech IGM Biosciences (Nasdaq: IGMS), which is developing and delivering medicines to treat patients with autoimmune and ...

IGM Financial Inc (IGIFF) reports record earnings and significant asset growth, while navigating market volatility and strategic challenges.

IGM Financial Inc. reported adjusted net earnings of $237.8 million for the first quarter, up 5.9% from the same quarter of ...

IGM Financial Inc. (TSX: IGM) held its Annual Meeting of Shareholders earlier today. All of the nominees for election as directors listed in its management proxy circular dated February 24, 2025 were ...

Cambridge, Massachusetts-based Vor Bio has confirmed that it will halt clinical and manufacturing operations, including its ...

After losing its powerhouse partner, IGM Biosciences closed “most” of its labs and offices and initiated a strategic review ...

Sanofi has scrapped its collaboration with IGM Biosciences, eliminating the biotech’s l | Sanofi has scrapped its ...

Scientists have engineered a monoclonal antibody that can protect mice from a lethal dose of influenza A, a new study shows. The new molecule combines the specificity of a mature flu fighter with the ...

Scientists have engineered a monoclonal antibody that can protect mice from a lethal dose of influenza A, a new study shows.